There are contraindications! Be sure to consult your doctor before taking any medication!
Cetapin-XR - Cetapin-XR is a biguanide antihyperglycemic agent used for treating non-insulin-dependent diabetes mellitus (NIDDM). It improves glycemic control by decreasing hepatic glucose production, decreasing glucose absorption and increasing insulin-mediated glucose uptake. Cetapin-XR is the only oral antihyperglycemic agent that is not associated with weight gain. Cetapin-XR may induce weight loss and is the drug of choice for obese NIDDM patients. When used alone, Cetapin-XR does not cause hypoglycemia; however, it may potentiate the hypoglycemic effects of sulfonylureas and insulin. Its main side effects are dyspepsia, nausea and diarrhea. Dose titration and/or use of smaller divided doses may decrease side effects. Cetapin-XR should be avoided in those with severely compromised renal function (creatinine clearance < 30 ml/min), acute/decompensated heart failure, severe liver disease and for 48 hours after the use of iodinated contrast dyes due to the risk of lactic acidosis. Lower doses should be used in the elderly and those with decreased renal function. Cetapin-XR decreases fasting plasma glucose, postprandial blood glucose and glycosolated hemoglobin (HbA1c) levels, which are reflective of the last 8-10 weeks of glucose control. Cetapin-XR may also have a positive effect on lipid levels.
Indication: For use as an adjunct to diet and exercise in adult patients (18 years and older) with NIDDM. May also be used for the management of metabolic and reproductive abnormalities associated with polycystic ovary syndrome (PCOS).
Cetapin-XR is an oral antihyperglycemic agent that improves glucose tolerance in patients with NIDDM, lowering both basal and postprandial plasma glucose. Cetapin-XR is not chemically or pharmacologically related to any other class of oral antihyperglycemic agents. Unlike sulfonylureas, Cetapin-XR does not produce hypoglycemia in either patients with NIDDM or healthy subjects and does not cause hyperinsulinemia. Cetapin-XR does not affect insulin secretion.
Pharmaceutical active ingredients containing related brand and generic drugs, medications or other health care products: